177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3 ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Androgen Receptor Pathway in Salivary Gland Cancer The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless ...

The approval of 3 androgen receptor pathway inhibitors (ARPIs) has given providers novel treatment options for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) that have ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen receptor axis have significantly delayed disease progression. However, drug ...

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why ...

Androgen receptor pathway inhibitors were shown to better treat patients with metastatic castration-resistant prostate cancer and improved survival.

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an ...

Barriers to adopting androgen receptor pathway inhibitors (ARPIs) in metastatic hormone-sensitive prostate cancer (mHSPC) treatment include cost, physician awareness, patient education, and ...